Market Shift

As licensing costs in China surge, biopharma companies are turning to AI-driven data analytics and the expertise of local partners. New strategies are required to alleviate cost pressure and maintain negotiating strength.

Rapid Rise of Chinese Companies

According to SynBioBeta data, Chinese firms account for 50% of global out‑licensing transactions. This is interpreted as a result of supportive government policies and abundant clinical data that enhance cost efficiency.

Declining Share of U.S. Companies

U.S. companies now represent only about 28% of total transactions. Rising costs and changes in the regulatory environment are pressuring U.S. firms to seek cost‑saving measures through local partners and AI tools.

Synergy of AI and Local Know‑How

AI accelerates candidate selection and market forecasting, while local firms help overcome regulatory and cultural barriers. Combined, these elements can secure more favorable licensing terms.

Broader Industry Impact

These developments are prompting global biopharma firms to recalibrate partnership strategies and are expected to expand demand for AI solution providers and local consulting firms.